Demircan Tan Berna, Turan Turgay, Yucel Burcu, Altundag Kara Sedef, Salman Yilmaz Seda, Yildirim Asif
Istanbul Medeniyet University, Faculty of Medicine Department of Medical Biology, Istanbul, Turkey.
Istanbul Medeniyet University, Faculty of Medicine, Department of Urology, Istanbul, Turkey.
Medeni Med J. 2020;35(2):99-105. doi: 10.5222/MMJ.2020.58708. Epub 2020 Jun 30.
The aim of this study was to investigate the promoter methylation status of Rasassociated domain family 1A (RASSF1A), O-6-methylguanine-DNA methyltransferase (MGMT), Phosphatase with tensin homology (PTEN) and Suppressor of cytokine signaling 3 (SOCS3) tumor suppressor genes and evaluate the clinical utility of these genes as noninvasive, blood-based epigenetic biomarkers for the diagnosis of Prostate Cancer (PCa).
A total of 41 consecutive patients and 10 healthy control groups were enrolled in the study. Pyrosequencing was performed to analyze the methylation levels of the promoter regions of the four tumor suppressor genes in patients compared to healthy controls.
The promoter methylation levels of RASSF1A, MGMT, PTEN and SOCS3 did not differ between the patient and control groups. However, SOCS3 promoter methylation level was significantly higher for patients having locally advanced PCa compared to those having localizedPCa (p<0.05).
Our results indicated that SOCS3 could be a useful, noninvasive blood-based epigenetic biomarker for the diagnosis of locally advanced PCa.
本研究旨在调查Ras相关结构域家族1A（RASSF1A）、O-6-甲基鸟嘌呤-DNA甲基转移酶（MGMT）、张力蛋白同源磷酸酶（PTEN）和细胞因子信号转导抑制因子3（SOCS3）等抑癌基因的启动子甲基化状态，并评估这些基因作为非侵入性、基于血液的表观遗传生物标志物在前列腺癌（PCa）诊断中的临床应用价值。
本研究共纳入41例连续患者和10个健康对照组。采用焦磷酸测序法分析患者与健康对照者中4个抑癌基因启动子区域的甲基化水平。
患者组与对照组之间，RASSF1A、MGMT、PTEN和SOCS3的启动子甲基化水平无差异。然而，与局限性前列腺癌患者相比，局部晚期前列腺癌患者的SOCS3启动子甲基化水平显著更高（p<0.05）。
我们的结果表明，SOCS3可能是一种用于诊断局部晚期前列腺癌的有用的、非侵入性的基于血液的表观遗传生物标志物。
